Skip to content

DART: Diagnostic-CT-Enabled Planning: A Randomized Trial in Palliative Radiation Therapy

DART: Diagnostic-CT-Enabled Planning: A Randomized Trial in Palliative Radiation Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05233904
Acronym
DART
Enrollment
33
Registered
2022-02-10
Start date
2022-06-08
Completion date
2023-08-01
Last updated
2022-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer Requiring Palliative Radiation

Brief summary

The objective of this trial is to assess the efficacy, acceptability, and scalability of diagnostic-CT-enabled planning, compared to conventional CT simulation planning.

Interventions

DIAGNOSTIC_TESTDiagnostic-CT-enabled Planning

Diagnostic-CT-enabled planning for patient receiving palliative radiation treatment to bone, soft tissue and lung disease

DIAGNOSTIC_TESTStandard of Care

Patients will be booked for CT simulation and treatment as per the local institution's standard practice

Sponsors

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or older * Able to provide informed consent * Patient has consented to PRT to bone/soft tissue metastases or primary targets in the thorax, abdomen, or pelvis and RO will use simple planning techniques (i.e. parallel-opposed pair or direct field beam arrangement) * Patient will be scheduled for same-day simulation and treatment (if randomized to Arm 1) * Patient has a pre-existing and recent (i.e. within 4 weeks of time of enrollment) diagnostic CT or CT-fused scan with full visualization of the region-of-interest which has been acquired from an approved diagnostic scanner * Patient positioning scan is deemed acceptable and reproducible (e.g., patient is lying supine and relatively flat, there is no/minimal motion blur, ect.) * Intravenous (IV)/oral contrast in the region-of-interest is permitted as long as it does not create artifact which obscured the target volume (density override calculations may be required)

Exclusion criteria

* Any contraindication to receiving radiation * Oncologic emergencies and/or on-call cases * Pregnant or lactating women * Cases requiring composite dosimetric planning to account for previous radiotherapy or extended distance set-up

Design outcomes

Primary

MeasureTime frameDescription
Time in Centre (TIC) on Treatment Day1 Treatment DayThis is defined as the total time in hours spent at the cancer centre from the scheduled CT simulation (Arrm 1) or treatment delivery (Arm 2) appointment until beam delivery completion.

Countries

Canada

Contacts

Primary ContactDavid Palma, MD
David.Palma@lhsc.on.ca519-685-8500
Backup ContactMelissa O'Neil
Melissa.ONeil@lhsc.on.ca

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026